<<how many companies could have been had for todays price divided by 2, 3, or even 4 just 6 months ago. >>
Most biotechs have "shareholder rights" plans in place. Realistically, they have to want to be bought. AGPH, SIBI, SUGN, CNTO, all went looking for a buyout, "big brother" didn't go looking for them. So, I think the answer to your question is: not many. They weren't for sale.
Who is for sale? Look for companies with lots of clinical plans but not too much money. That takes NBIX, for example, out of the "munch" picture, because they're flush with cash. Same with SNAP, from another point of view --- decent cash and no big clinical trial drain on cash.
TD |
